SPDR S&P Biotech ETF
XBI

$101.58

0.83%

Market Cap: $7.77B

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 249 | Existing positions reduced: 248

2% less funds holding

Funds holding: 764 [Q1] → 745 (-19) [Q2]

8.9% less ownership

Funds ownership: 138.71% [Q1] → 129.81% (-8.9%) [Q2]

12% less capital invested

Capital invested by funds: $10.4B [Q1] → $9.15B (-$1.27B) [Q2]

18% less first-time investments, than exits

New positions opened: 87 | Existing positions closed: 106

22% less funds holding in top 10

Funds holding in top 10: 23 [Q1] → 18 (-5) [Q2]

51% less call options, than puts

Call options by funds: $1.59B | Put options by funds: $3.25B

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for XBI.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about XBI published over the past 30 days

XBI Is Breaking Out And Likely To Outperform In The Near Term (Technical Analysis)

Biotechnology equities have underperformed since late 2020, but recent acquisitions and drug approvals suggest a potential industry revaluation. SPDR S&P Biotech ETF (XBI) offers broad exposure to the biotech sector, with equal weighting reducing susceptibility to individual stock movements. XBI shows strong support around $96 and $90, with the potential to break resistance at $102.50, especially if the Federal Reserve cuts rates.

XBI Is Breaking Out And Likely To Outperform In The Near Term (Technical Analysis)

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

Zacks Investment Research

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

A smart beta exchange traded fund, the SPDR S&P Biotech ETF (XBI) debuted on 01/31/2006, and offers broad exposure to the Health Care ETFs category of the market.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

CNBC Television

Trade Tracker: Joe Terranova sells the ITA and XBI

Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's selling these two ETFs.

Trade Tracker: Joe Terranova sells the ITA and XBI

Biopharmaceutical Stocks: The Next Phase Of The Rally Appears To Be Underway

Stock valuations in the pharmaceutical industry are becoming more attractive for potential mergers due to declining IPO prices. Aging population and prevalence of chronic diseases are driving favorable prospects for the drug industry.

Biopharmaceutical Stocks: The Next Phase Of The Rally Appears To Be Underway

CNBC Television

Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross

Michelle Ross, Stempoint Capital, joins 'Closing Bell' to discuss Eli Lilly after the stock saw a slight dip after rallying.

Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross

Bond ETFs attract record flows in July as investors position for Fed rate cuts

Hello! Bonds seemed more appealing to ETF investors than ever before in July, based on flow data from State Street. This week's ETF Wrap looks at what's driving investors' appetite for fixed income lately, and where their money flowed within fixed income.

Bond ETFs attract record flows in July as investors position for Fed rate cuts

Zacks Investment Research

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

The SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

CNBC Television

Final Trades: Amazon, Truist Financial and the XBI

The Investment Committee give you their top stocks to watch for the second half.

Final Trades: Amazon, Truist Financial and the XBI

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and, along with rising unemployment, should persuade the Fed to cut rates this year in September.

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

See News Rankings